Foley & Lardner LLP Partner Kyle Faget was quoted in the MedTech Dive article, “3 key FDA topics for medtechs in 2022,” about the October 2021 release of the FDA’s list of proposed draft and final medical device guidance documents for fiscal year 2022, including the final guidance on clinical decision support (CDS) software.
Faget said that “The risk-based approach to enforcement that FDA issued previously is not easy for [technology] developers to follow. FDA needs to provide more clarity for developers as to where the boundaries are for each one of those categories.”
Faget is co-chair of Foley’s Health Care and Life Sciences Practice Groups.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“